BioWorld
-
Azeria adds $41M to pioneer FOXA1 approach in breast cancer
-
Harpoon snares an expanded agreement with Abbvie
-
Hua Medicine achieves primary efficacy endpoint in phase III trial for type 2 diabetes candidate
-
Primed with phase III glioblastoma data, Diffusion seeks partner for next step
-
China’s first AI microbiome firm Xbiome raises over $14M in series B
-
Lucence attracts $20M in series A to scale up operations
-
Alnylam wins FDA approval for new porphyria therapy
-
Hahn steers clear of controversy in Senate hearing for FDA job
-
Aravive apperceived: Invariant ovarian outcome backs first phase Ib results
BioWorld MedTech
-
Livanova unveils plans to restructure heart valve business, end TMVR program
-
Med-tech IPO 2019 stocks up 43% led by aesthetics company Inmode
-
FDA offers no apparent grace period for 510(k)s under safety and performance framework
-
Lucence attracts $20M in series A to scale up operations
-
Bioworld MedTech’s Diagnostics extra
-
BioWorld MedTech Patent Highlights - Week 46
-
Hologic to sell off 'underperforming' Cynosure, will focus on tuck-ins
-
Tissium raises €39M to expand surgical sealant, add 3D printed and drug-delivery applications
-
FDA clears Carestream’s Dual-Energy radiography technology, Focus 35C detector
BioWorld Asia
-
China looking to close gap in cell therapy market; CAR T development advancing fast
-
SL Bigen secures ₩3B from Yuhan for CAR-NK therapy
-
FDA approval of Shionogi antibacterial sets stage for move into new market
-
Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say
-
Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out
-
Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs
-
Aslan's varlitinib clinical study for BTC patients failed to meet primary endpoints
-
Akeso closes $150M series D to advance first-in-class bispecific antibodies
-
Tot Biopharm raises $61M on HKEX, co-develops antibody with Harbour
